ICER Report Suggests Significant Price Reduction for Pfizer’s ATTR-CM Drug Tafamidis

ICER Report:
The Institute for Clinical and Economic Review (ICER) has published a revised Evidence Report on treatments for transthyretin amyloid cardiomyopathy (ATTR-CM), including Pfizer's tafamidis (Vyndamax/Vyndaqel).

Cost-Effectiveness:
ICER calculated a health benefit price benchmark (HBPB) for TTR stabilizers like tafamidis and acoramidis to be between $13,600 to $39,000 per year, indicating that tafamidis, currently priced at approximately $268,000 per year, is not cost-effective at its current price.

Pricing Concerns:
The report suggests that a significant price reduction, up to 92.6%, would be necessary to make tafamidis cost-effective at a commonly accepted threshold of $100,000 per quality-adjusted life year (QALY) gained.

Clinical Benefits:
Tafamidis provides a net health benefit compared to no disease-specific therapy, but with moderate certainty regarding the magnitude of these benefits.

Healthcare Spending Impact:
Widespread uptake of tafamidis at its current price could lead to a substantial increase in healthcare spending, estimated at $32.3 billion annually in the US.